All our programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is working on the development of two series of receptor-targeted toxins that will bind to certain cells (GnRH neurons or gonadotrophs) and deliver highly potent protein toxins that should specifically and effectively induce sterility.